capivasertib,AZD5363
astrazeneca,otsuka
['bcsm', 'mbc', 'capivasertib']
faktion
fulvestrant plus capivasertib vs. placebo mpfs 10.3mos vs 4.8 mos improved pfs (12.8mo vs 4.6mo) and os in expanded pathway altered group. highlights importance ngs which identified (54% vs. 42%) #mbc #bcsm #asco22 
Breast Medical Oncologist @RutgersCancer @Rutgers and @RWJMS wife/mom/baker/world traveler #bcsm